Evidence map›Paper›PMID 34606010›Full record

ArticleNano convergence2021

PFP@PLGA/Cu

Tianxiu Dong, Jian Jiang, Hao Zhang, Hongyuan Liu, Xiaomeng Zou, Jiamei Niu, Yingxuan Mao, Mingwei Zhu, Xi Chen, Zizhuo Li and 3 more

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano convergence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Correction to: PFP@PLGA/CuNano convergence · 2024
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Tianxiu Dong *Department of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Jian Jiang *Department of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Hao ZhangDepartment of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Hongyuan LiuDepartment of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Xiaomeng ZouDepartment of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Jiamei NiuDepartment of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Yingxuan MaoDepartment of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Mingwei ZhuDepartment of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Xi ChenDepartment of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Zizhuo LiDepartment of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Yaodong ChenDepartment of Ultrasonic Imaging, First Hospital of Shanxi Medical University, Taiyuan, 030001, China.
Chunying ShiDepartment of Radiology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Xiuhua YangDepartment of Abdominal Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China. yangxiuhua@hrbmu.edu.cn.
Harbin Medical University · CNFirst Affiliated Hospital of Harbin Medical University · CNShanxi Medical University · CN

Funding

China Postdoctoral Science Foundation 2018M641850Natural Science Foundation of China 81871362the Fund of Scientific Research Innovation of The First Affiliated Hospital of Harbin Medical University 2018B009
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most malignant tumors in the world, and patients with HCC face a poor prognosis. The conventional therapeutic strategies for HCC have undergone a challenge-riddled evolution owing to side effects and unsatisfactory efficacy. Here, aiming to provide a new method of HCC elimination, we formulated a novel multifunctional nanocapsule (PFP@PLGA/Cu

Indexed as

Hepatocellular carcinomaNanocapsulePhotothermal therapyThermal ablation

Identifiers

PMID34606010
PMCPMC8490557
OpenAlexW3204926178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.